Novo Nordisk | NVO - Interest Expense On Debt


Novo Nordisk reported DKK82.1M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Aurora Cannabis CAD 2.11M 116K Dec/2025
Bausch Health Companies USD 397M 15M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Canopy Growth CAD 7.34M 1.46M Dec/2025
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Drreddys Laboratories INR 944M 127M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
Merck USD 479M 67M Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 343M 39M Mar/2026
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Sanofi EUR 178M 203M Mar/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 62M 5M Mar/2026